{"id":5213,"date":"2022-03-22T13:59:18","date_gmt":"2022-03-22T13:59:18","guid":{"rendered":"https:\/\/www.nfp-drugs.bg\/en\/?p=5213"},"modified":"2022-04-05T13:59:59","modified_gmt":"2022-04-05T13:59:59","slug":"selected-issues-emcdda","status":"publish","type":"post","link":"https:\/\/www.nfp-drugs.bg\/en\/selected-issues-emcdda\/","title":{"rendered":"Selected Issues (EMCDDA)"},"content":{"rendered":"\n

(37) Prisons and drugs in Europe: the problem and responses (2012)<\/a><\/p>\n\n\n\n

(36) Pregnancy, childcare and the family: key issues for Europe\u2019s response to drugs (2012)<\/a><\/p>\n\n\n\n

(35) Mortality related to drug use in Europe (2011)<\/a><\/p>\n\n\n\n

(34) Cost and financing of drug treatment services in Europe (2011)<\/a><\/p>\n\n\n\n

(33) Guidelines for the treatment of drug dependence: a European perspective (2011)<\/a><\/p>\n\n\n\n

(32) Problem amphetamine and methamphetamine use in Europe (2010)<\/a><\/p>\n\n\n\n

(31) Treatment and care for older drug users (2010)<\/a><\/p>\n\n\n\n

(30) Trends in injecting drug use in Europe (2010)<\/a><\/p>\n\n\n\n

(29) Polydrug use: patterns and responses (2009)<\/a><\/p>\n\n\n\n

(28) Drug offences: sentencing and other outcomes (2009)<\/a><\/p>\n\n\n\n

(27)National drug-related research in Europe (2008)<\/a><\/p>\n\n\n\n

(26) Towards a better understanding of drug-related public expenditure in Europe (2008)<\/a><\/p>\n\n\n\n

(25) Drugs and vulnerable groups of young people (2008)<\/a><\/p>\n\n\n\n

(24) Cocaine and crack cocaine: a growing public health issue (2007)<\/a><\/p>\n\n\n\n

(23) Drugs and driving (2007)<\/a><\/p>\n\n\n\n

(22) Drug use and related problems among very young people (under 15 years old) (2007)<\/a><\/p>\n\n\n\n

(21) Developments in drug use within recreational settings (2006)<\/a><\/p>\n\n\n\n

(20)European drug policies: extended beyond illicit drugs? (2006)<\/a><\/p>\n\n\n\n

(19) A gender perspective on drug use and responding to drug problems (2006)<\/a><\/p>\n\n\n\n

(18) Alternatives to imprisonment \u2014 targeting offending problem drug users in the EU (2005)<\/a><\/p>\n\n\n\n

(17) Drug-related public nuisance \u2014 trends in policy and preventive measures (2005)<\/a><\/p>\n\n\n\n

(16) Buprenorphine \u2014 treatment, misuse and prescription practices (2005)<\/a><\/p>\n\n\n\n

(15) Co-morbidity (2004)<\/a><\/p>\n\n\n\n

(14) Cannabis problems in context: understanding the increase in European treatment demands (2004)<\/a><\/p>\n\n\n\n

(13) Evaluation of \u2018national drug strategies\u2019 in Europe (2004)<\/a><\/p>\n\n\n\n

(12) Public expenditure in the area of drug-demand reduction (2003)<\/a><\/p>\n\n\n\n

(11) Drug and alcohol use among young people (2003)<\/a><\/p>\n\n\n\n

(10) Social exclusion and reintegration (2003)<\/a><\/p>\n\n\n\n

(9) Successful treatment (2002)<\/a><\/p>\n\n\n\n

(8) Polydrug use (2002)<\/a><\/p>\n\n\n\n

(7) Drug use in prison (2002)<\/a><\/p>\n\n\n\n

(6) Infectious diseases (2001)<\/a><\/p>\n\n\n\n

(5) Synthetic drugs (2001)<\/a><\/p>\n\n\n\n

(4) Cocaine and \u2018base\/crack\u2019 cocaine (2001)<\/a><\/p>\n\n\n\n

(3) Prosecution of drug-related offences (2000)<\/a><\/p>\n\n\n\n

(2) Substitution treatment (2000)<\/a><\/p>\n\n\n\n

(1) Problems facing women drug users and their children (2000)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

(37) Prisons and drugs in Europe: the problem and responses (2012) (36) Pregnancy, childcare and the family: key issues for Europe\u2019s response to drugs (2012) (35) Mortality related to drug use in Europe (2011) (34) Cost and financing of drug treatment services in Europe (2011) (33) Guidelines for the treatment of drug dependence: a European […]<\/p>\n","protected":false},"author":1,"featured_media":5214,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,11],"tags":[59,58,68],"_links":{"self":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5213"}],"collection":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/comments?post=5213"}],"version-history":[{"count":2,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5213\/revisions"}],"predecessor-version":[{"id":5482,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5213\/revisions\/5482"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media\/5214"}],"wp:attachment":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media?parent=5213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/categories?post=5213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/tags?post=5213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}